EGFR and non-small cell lung carcinoma: Furthermore, data from Surveillance, Epidemiology, and End Results (SEER) have highlighted improvements in incidence-based mortality greater than in previous periods since 2013, in men, and since 2014, in women, considering that since 2013, the use of EGFR inhibitors has been approved as a first-line treatment for advanced NSCLC [7].